300765 新诺威
已收盘 03-20 15:00:00
资讯
新帖
简况
股市必读：新诺威（300765）3月18日披露最新机构调研信息
证券之星 · 03-19
股市必读：新诺威（300765）3月18日披露最新机构调研信息
新诺威：3月17日接受机构调研，包括知名机构淡水泉，高毅资产的多家机构参与
证券之星 · 03-18
新诺威：3月17日接受机构调研，包括知名机构淡水泉，高毅资产的多家机构参与
新诺威最新公告：2025年亏损2.41亿元同比由盈转亏
证券之星 · 03-16
新诺威最新公告：2025年亏损2.41亿元同比由盈转亏
3月16日新诺威涨6.70%，工银前沿医疗股票A基金重仓该股
证券之星 · 03-16
3月16日新诺威涨6.70%，工银前沿医疗股票A基金重仓该股
新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，3月13日股价下跌1.74%
证券之星 · 03-13
新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，3月13日股价下跌1.74%
股市必读：3月10日新诺威现1233.98万元大宗交易
证券之星 · 03-11
股市必读：3月10日新诺威现1233.98万元大宗交易
新诺威：截至2026年2月27日股东数为19,761户
证券之星 · 03-05
新诺威：截至2026年2月27日股东数为19,761户
新诺威(300765.SZ)：艾美赛珠单抗注射液获准开展临试
智通财经 · 03-04
新诺威(300765.SZ)：艾美赛珠单抗注射液获准开展临试
3月2日新诺威发生2笔大宗交易 成交金额598.48万元
证券之星 · 03-02
3月2日新诺威发生2笔大宗交易 成交金额598.48万元
新诺威（300765）披露转让参股公司股份暨关联交易公告，2月26日股价下跌2.72%
证券之星 · 02-26
新诺威（300765）披露转让参股公司股份暨关联交易公告，2月26日股价下跌2.72%
新诺威最新公告：拟2.3亿元转让国新汇金30%股份给石药控股
证券之星 · 02-26
新诺威最新公告：拟2.3亿元转让国新汇金30%股份给石药控股
新诺威（300765）披露控股子公司及关联方与阿斯利康签署战略合作与授权协议暨关联交易议案获通过，2月24日股价下跌0.42%
证券之星 · 02-24
新诺威（300765）披露控股子公司及关联方与阿斯利康签署战略合作与授权协议暨关联交易议案获通过，2月24日股价下跌0.42%
新诺威最新公告：控股子公司巨石生物SYS6023ADC药物获批临床试验
证券之星 · 02-12
新诺威最新公告：控股子公司巨石生物SYS6023ADC药物获批临床试验
2月5日新诺威发生1笔大宗交易 成交金额793.94万元
证券之星 · 02-05
2月5日新诺威发生1笔大宗交易 成交金额793.94万元
新诺威：截至2026年1月30日股东数为17,481户
证券之星 · 02-03
新诺威：截至2026年1月30日股东数为17,481户
股市必读：新诺威（300765）1月30日收盘跌15.72%，主力净流出1077.35万元
证券之星 · 02-02
股市必读：新诺威（300765）1月30日收盘跌15.72%，主力净流出1077.35万元
“90后”董秘“逆袭”成500亿市值公司总经理，新诺威业绩不振亟待扭转
蓝鲸财经 · 01-30
“90后”董秘“逆袭”成500亿市值公司总经理，新诺威业绩不振亟待扭转
1月30日新诺威（300765）龙虎榜数据：机构净卖出7481.52万元，北向资金净买入412.42万元
证券之星 · 01-30
1月30日新诺威（300765）龙虎榜数据：机构净卖出7481.52万元，北向资金净买入412.42万元
1月30日新诺威跌15.72%，工银前沿医疗股票A基金重仓该股
证券之星 · 01-30
1月30日新诺威跌15.72%，工银前沿医疗股票A基金重仓该股
新诺威最新公告：控股子公司及关联方共同与阿斯利康签署战略合作与授权协议
证券之星 · 01-30
新诺威最新公告：控股子公司及关联方共同与阿斯利康签署战略合作与授权协议
加载更多
公司概况
公司名称：
石药创新制药股份有限公司
所属行业：
食品制造业
上市日期：
2019-03-22
主营业务：
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格：
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"新诺威","latestPrice":30.16,"timestamp":1773990228000,"preClose":31.65,"halted":0,"volume":8958748,"delay":0,"changeRate":-0.0471,"floatShares":1405000000,"shares":1405000000,"eps":-0.3816,"marketStatus":"已收盘","change":-1.49,"latestTime":"03-20 15:00:00","open":31.79,"high":32.13,"low":30,"amount":278000000,"amplitude":0.0673,"askPrice":30.2,"askSize":49,"bidPrice":30.16,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.3816,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"adjPreClose":31.65,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":34.82,"lowLimit":28.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":16.67,"roa":"--","roe":"--","epsLYR":-0.1731,"committee":0.5525,"marketValue":42363000000,"turnoverRate":0.0064,"status":1,"floatMarketCap":42363000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2620266746","title":"股市必读：新诺威（300765）3月18日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620266746?lang=zh_cn&edition=full","pubTime":"2026-03-19 02:18","pubTimestamp":1773857893,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，新诺威报收于32.05元，下跌0.93%，换手率0.54%，成交量7.56万手，成交额2.42亿元。当日关注点来自交易信息汇总：3月18日主力资金净流出153.66万元，散户资金净流入235.38万元。另外国内正在进行的 EGFR突变型肺癌3期临床试验已经完成入组，目前正在受试者随访中。的首个完整销售年度，公司生物制药业务收入实现显著增长。2026年，随着销售团队的持续扩充及市场推广力度的加大，公司看好生物制药业务的发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900001196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2620528807","title":"新诺威：3月17日接受机构调研，包括知名机构淡水泉，高毅资产的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2620528807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620528807?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:30","pubTimestamp":1773801034,"startTime":"0","endTime":"0","summary":"2026年以来，咖啡因价格趋于稳定，后续公司会持续关注咖啡因的价格走势。除上述临床外，公司也在积极推进食管鳞癌，乳腺癌等适应症。的首个完整销售年度，公司生物制药业务收入实现显著增长。2026年，随着销售团队的持续扩充及市场推广力度的加大，公司看好生物制药业务的发展。新诺威主营业务：生物制药和功能食品及原料的研发、生产和销售。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800013153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2619450921","title":"新诺威最新公告：2025年亏损2.41亿元同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450921","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619450921?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:40","pubTimestamp":1773661237,"startTime":"0","endTime":"0","summary":"新诺威发布2025年年度报告，2025年公司实现营业收入为21.58亿元，同比增长8.93%，归属于上市公司股东的净利润-2.41亿元，同比由盈转亏；基本每股收益-0.1731元。2025年公司投入研发费用10.36亿元，同比增长23.01%。公司在研项目众多，截至2025年末，公司拥有十余款处于临床或后期开发阶段的主要在研药物，其中乌司奴单抗注射液、帕妥珠单抗注射液已递交上市申请，多个项目处于关键临床试验阶段，这些研发成果将有望成为公司未来业绩增长的驱动引擎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600030714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2619453530","title":"3月16日新诺威涨6.70%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453530","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453530?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:27","pubTimestamp":1773649673,"startTime":"0","endTime":"0","summary":"证券之星消息，3月16日新诺威涨6.70%，收盘报32.0元，换手率1.0%，成交量14.03万手，成交额4.43亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共38家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600021717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"gpt_icon":0},{"id":"2619115965","title":"新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，3月13日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115965","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619115965?lang=zh_cn&edition=full","pubTime":"2026-03-13 22:34","pubTimestamp":1773412461,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，新诺威报收于29.99元，较前一交易日下跌1.74%，最新总市值为421.24亿元。该股当日开盘30.48元，最高30.66元，最低29.76元，成交额达1.83亿元，换手率为0.43%。新诺威于近日披露《关于使用部分闲置募集资金进行现金管理的进展公告》。公告显示，公司及子公司使用不超过8.00亿元的闲置募集资金进行现金管理，投资安全性高、流动性好的保本型产品。上述现金管理事项在股东大会授权范围内，无需另行审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300041799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2618237950","title":"股市必读：3月10日新诺威现1233.98万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2618237950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618237950?lang=zh_cn&edition=full","pubTime":"2026-03-11 01:33","pubTimestamp":1773163990,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘，新诺威报收于31.82元，上涨3.11%，换手率0.75%，成交量10.47万手，成交额3.34亿元。来自交易信息汇总：同日游资资金净流入1011.82万元，反映短线交易热度上升。来自交易信息汇总：新诺威当日发生1233.98万元大宗交易，可能暗示机构间仓位调整。交易信息汇总资金流向3月10日主力资金净流出738.79万元；游资资金净流入1011.82万元；散户资金净流出273.03万元。大宗交易3月10日新诺威现1233.98万元大宗交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100000709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2617548237","title":"新诺威：截至2026年2月27日股东数为19,761户","url":"https://stock-news.laohu8.com/highlight/detail?id=2617548237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617548237?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:09","pubTimestamp":1772705350,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司2月末股东人数多少？谢谢新诺威回复：您好，感谢您对公司的关注，截至2026年2月27日，公司合并普通账户和融资融券信用账户股东数为19,761户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500030928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2616582488","title":"新诺威(300765.SZ)：艾美赛珠单抗注射液获准开展临试","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582488","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616582488?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:46","pubTimestamp":1772610394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威(300765.SZ)公告，公司控股子公司石药集团巨石生物制药有限公司(简称“巨石生物”)于近日收到国家药品监督管理局核准签发的关于艾美赛珠单抗注射液(SYS6053)的《药物临床试验批准通知书》，将于近期开展临床试验。该产品是一种修饰的人源化IgG4单克隆抗体，具有双特异性抗体结构，可桥接凝血因子IXa和凝血因子X，为原研药舒友立乐®的生物类似药，按照治疗用生物制品3.3类申报，适用于A型血友病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新诺威(300765.SZ)：艾美赛珠单抗注射液获准开展临试","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2616387869","title":"3月2日新诺威发生2笔大宗交易 成交金额598.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616387869?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:23","pubTimestamp":1772443404,"startTime":"0","endTime":"0","summary":"证券之星消息，3月2日新诺威发生大宗交易，交易数据如下：近三个月该股共发生7笔大宗交易，合计成交1.93万手。该股在过去半年内已有共计1.58亿股限售解禁股上市，占公司总股本的11.21%。截至2026年3月2日收盘，新诺威(300765)报收于31.4元，下跌4.93%，换手率0.72%，成交量10.09万手，成交额3.2亿元。该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200024840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2614028282","title":"新诺威（300765）披露转让参股公司股份暨关联交易公告，2月26日股价下跌2.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028282","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614028282?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:29","pubTimestamp":1772116154,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，新诺威报收于32.87元，较前一交易日下跌2.72%，最新总市值为461.69亿元。该股当日开盘33.7元，最高33.79元，最低32.61元，成交额达2.68亿元，换手率为0.58%。近日，新诺威披露《关于转让参股公司股份暨关联交易的公告》。公告显示，公司拟将持有的北京国新汇金股份有限公司30.0704%股份，以23,000.00万元的价格转让给关联方石药控股集团有限公司。本次交易构成关联交易，已经公司董事会及独立董事专门会议审议通过，尚需股东会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2614828019","title":"新诺威最新公告：拟2.3亿元转让国新汇金30%股份给石药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2614828019","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614828019?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:22","pubTimestamp":1772097752,"startTime":"0","endTime":"0","summary":"新诺威(300765.SZ)公告称，公司拟将持有的国新汇金30.0704%股份以2.3亿元价格转让给石药控股，转让完成后，公司将不再持有国新汇金股份。该交易已获公司董事会通过，尚需股东会批准。交易定价参考了国融兴华资产评估有限责任公司的评估结果，增值率94.85%。所得款项将用于补充公司日常运营资金。国新汇金是以移动资讯客户端、全媒体矩阵为核心的全媒体传播业务平台。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600026468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999004220.SGD","LU1008478684.HKD","BK1191","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1226287792.SGD","LU1226288253.USD","LU0072913022.USD","BK1521","IE0008368742.USD","LU1807302812.USD","01093","LU1960683339.HKD","IE00BZ08YR35.GBP","LU1993786604.SGD","LU0315179316.USD","IE00BZ08YT58.USD","IE00B543WZ88.USD","HK0000165453.HKD","LU0501845795.SGD","LU1813983027.USD","LU1226287529.USD","LU1226288170.HKD","LU1951186391.HKD","LU0314109678.HKD","IE0008369823.USD","LU1226287875.USD","LU0140636845.USD","LU1328277881.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1152091168.USD","IE00B031HY20.USD","LU2039709279.SGD","BK0226","LU0067412154.USD","BK1515","300765"],"gpt_icon":0},{"id":"2613255797","title":"新诺威（300765）披露控股子公司及关联方与阿斯利康签署战略合作与授权协议暨关联交易议案获通过，2月24日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613255797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613255797?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:48","pubTimestamp":1771930097,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，新诺威报收于33.44元，较前一交易日下跌0.42%，最新总市值为469.7亿元。新诺威于近日披露《2026年第一次临时股东会决议公告》。公告显示，石药创新制药股份有限公司于2026年2月24日召开2026年第一次临时股东会，会议审议通过了《关于控股子公司及关联方共同与阿斯利康签署战略合作与授权协议暨关联交易的议案》。出席股东共381人，代表股份116,520,295股，占公司有表决权股份总数的8.3671%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2610333944","title":"新诺威最新公告：控股子公司巨石生物SYS6023ADC药物获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2610333944","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610333944?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:20","pubTimestamp":1770891644,"startTime":"0","endTime":"0","summary":"新诺威公告称，公司控股子公司巨石生物收到国家药品监督管理局核准签发关于SYS6023的《药物临床试验批准通知书》，同意开展在不可切除局部晚期或转移性乳腺癌的联合用药的临床试验。SYS6023是一款HER3靶向抗体偶联药物，采用公司自主研发的拓扑异构酶I抑制剂为载荷。根据国家药品注册相关的法律法规要求，药物在获得《药物临床试验批准通知书》后，尚需开展临床试验，并经国家监管部门批准后方可上市、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200030612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2609232010","title":"2月5日新诺威发生1笔大宗交易 成交金额793.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609232010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609232010?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:26","pubTimestamp":1770283586,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日新诺威发生大宗交易，交易数据如下：大宗交易成交价格34.67元，成交22.9万股，成交金额793.94万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生5笔大宗交易，合计成交1.74万手。该股在过去半年内已有共计1.58亿股限售解禁股上市，占公司总股本的11.21%。截至2026年2月5日收盘，新诺威报收于34.67元，下跌3.16%，换手率0.72%，成交量10.09万手，成交额3.53亿元。该股最近90天内无机构评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500027926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2608824427","title":"新诺威：截至2026年1月30日股东数为17,481户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608824427?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:12","pubTimestamp":1770113524,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问1月31日公司股东人数是多少？谢谢！新诺威回复：您好，感谢您对公司的关注，截至2026年1月30日，公司合并普通账户和融资融券信用账户股东数为17,481户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300032192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2608723886","title":"股市必读：新诺威（300765）1月30日收盘跌15.72%，主力净流出1077.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608723886","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608723886?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:52","pubTimestamp":1769971929,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，新诺威报收于38.87元，下跌15.72%，换手率2.5%，成交量35.07万手，成交额14.52亿元。当日关注点来自交易信息汇总：新诺威股价跌15.72%登上龙虎榜，主力资金当日净流出1077.35万元，游资大举净流入6503.2万元。该股已连续2日下跌。前10个交易日主力资金累计净流入1.31亿元，股价累计下跌2.97%；融资余额累计增加5157.6万元，融券余量累计减少9.52万股。因日跌幅达到15%，新诺威于1月30日登上龙虎榜，为近5个交易日内首次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2607036019","title":"“90后”董秘“逆袭”成500亿市值公司总经理，新诺威业绩不振亟待扭转","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036019","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036019?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:32","pubTimestamp":1769769175,"startTime":"0","endTime":"0","summary":"此次人事调整中，最引人瞩目的莫过于“90后”戴龙的职务晋升。值得注意的是，人事变动公告发布同日，新诺威还发布了一则关联交易公告。对此，1月30日，记者发函并多次致电新诺威，截至发稿尚未获得回应。不过，近年来，公司业绩出现大幅度下滑。2025年，公司业绩依旧承压。目前公司业绩不振，如何扭转业绩颓势，推动传统业务企稳回升、创新业务快速放量，是戴龙上任后面临的首要任务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769766339193787763","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2607013055","title":"1月30日新诺威（300765）龙虎榜数据：机构净卖出7481.52万元，北向资金净买入412.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607013055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607013055?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:32","pubTimestamp":1769765528,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月30日公布的交易公开信息显示，新诺威因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月30日收盘，新诺威报收于38.87元，下跌15.72%，换手率2.5%，成交量35.07万手，成交额14.52亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出7481.52万元，北向资金合计净买入412.42万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000030800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2607090135","title":"1月30日新诺威跌15.72%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090135","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090135?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:43","pubTimestamp":1769762588,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日新诺威跌15.72%，收盘报38.87元，换手率2.5%，成交量35.07万手，成交额14.52亿元。重仓新诺威的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共38家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000028052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"gpt_icon":0},{"id":"2607068852","title":"新诺威最新公告：控股子公司及关联方共同与阿斯利康签署战略合作与授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607068852?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:12","pubTimestamp":1769731966,"startTime":"0","endTime":"0","summary":"新诺威公告，公司的控股子公司巨石生物及公司的关联方石药集团、中奇制药共同与阿斯利康于1月29日签署《战略合作与授权协议》，将与阿斯利康在创新多肽分子发现和长效递送产品的开发领域开展全面战略合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000007085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774150121336,"stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.1018},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.4083},{"period":"1year","weight":-0.1889},{"period":"ytd","weight":-0.1638}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"19761人(较上一季度增加0.00%)","perCapita":"71079股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新诺威(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新诺威(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新诺威,300765,新诺威股票,新诺威股票老虎,新诺威股票老虎国际,新诺威行情,新诺威股票行情,新诺威股价,新诺威股市,新诺威股票价格,新诺威股票交易,新诺威股票购买,新诺威股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新诺威(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新诺威(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}